Chen Binghe, Zhang Dezhong, Kuai Jun, Cheng Mingkun, Fang Xiangjie, Li Guangyan
1 Department of Gastrointestinal Surgery, The First Affiliated Hospital of Xinxiang Medical University, Weihui, People's Republic of China.
2 ICU, The First Affiliated Hospital of Xinxiang Medical University, Weihui, People's Republic of China.
Tumour Biol. 2017 Jun;39(6):1010428317715155. doi: 10.1177/1010428317715155.
Cisplatin resistance in colorectal cancer largely results from the colorectal cancer stem cells which could be targeted to improve the efficacy of chemotherapy. MicroRNAs are possible modulators of cancer stem cell characteristics and maybe involved in the retention of cancer stem cell chemoresistance. The aim of this study was to investigate the biological function of miR-199a/b on cisplatin resistance in colorectal cancer stem cells and its related mechanisms. Here, ALDHA1 cells from primary colorectal cancer tissues behaved similar to cancer stem cells and were chemoresistant to cisplatin. The presence of a variable fraction of ALDHA1 was detected in 9 out of 10 colorectal cancer specimens. Significantly, increased miR-199a/b expression was detected in ALDHA1 colorectal cancer stem cells, accompanied by a downregulation of Gsk3β and an overexpression of β-catenin and ABCG2. In patient cohort, enhanced miR-199a/b expression in colorectal cancer tissues was associated with cisplatin response and poor patient survival. In addition, 80% of colorectal cancer samples showed lower level of Gsk3β than their adjacent normal counterparts. Furthermore, Gsk3β was the direct target of miR-199a/b. MiR-199a/b regulated Wnt/β-catenin pathway by targeting Gsk3β in ALDHA1 colorectal cancer stem cells. By blocking Wnt/β-catenin pathway, we implied that ABCG2 lies downstream of Wnt/β-catenin pathway. ABCG2 was further demonstrated to contribute cisplatin resistance in ALDHA1 colorectal cancer stem cells and can be regulated by miR-199a/b. Thus, our data suggested that upregulation of miR-199a/b in ALDHA1 colorectal cancer stem cells contributed to cisplatin resistance via Wnt/β-catenin-ABCG2 signaling, which sheds new light on understanding the mechanism of cisplatin resistance in colorectal cancer stem cells and facilitates the development of potential therapeutics against colorectal cancer.
结直肠癌中的顺铂耐药主要源于结直肠癌干细胞,靶向这些干细胞有望提高化疗疗效。微小RNA可能是癌症干细胞特性的调节因子,或许参与了癌症干细胞化疗耐药性的维持。本研究旨在探讨miR-199a/b对结直肠癌干细胞顺铂耐药的生物学功能及其相关机制。在此,来自原发性结直肠癌组织的ALDHA1细胞表现出与癌症干细胞相似的特性,且对顺铂具有化疗耐药性。在10个结直肠癌标本中的9个检测到了不同比例的ALDHA1细胞。值得注意的是,在ALDHA1结直肠癌干细胞中检测到miR-199a/b表达增加,同时伴有Gsk3β的下调以及β-连环蛋白和ABCG2的过表达。在患者队列中,结直肠癌组织中miR-199a/b表达增强与顺铂反应及患者不良生存相关。此外,80%的结直肠癌样本显示Gsk3β水平低于其相邻的正常组织。此外,Gsk3β是miR-199a/b的直接靶点。miR-199a/b通过靶向ALDHA1结直肠癌干细胞中的Gsk3β调节Wnt/β-连环蛋白通路。通过阻断Wnt/β-连环蛋白通路,我们推测ABCG2位于Wnt/β-连环蛋白通路的下游。进一步证实ABCG2在ALDHA1结直肠癌干细胞中导致顺铂耐药,且可受miR-199a/b调控。因此,我们的数据表明,ALDHA1结直肠癌干细胞中miR-199a/b的上调通过Wnt/β-连环蛋白-ABCG2信号通路导致顺铂耐药,这为理解结直肠癌干细胞中顺铂耐药机制提供了新的线索,并有助于开发针对结直肠癌的潜在治疗方法。